AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05169645 — intervention group
Intervention type: OTHER
Intervention: Physical activity monitoring - Symptom monitoring
Description: This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months.~The Fitbit measures:~* Physical activity using daily step count~* Additional physical activity entries~* Heart rate~* Sleep quality~* Calories burned~* Food log~Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture:~* Urticaria symptomatology using the urticaria control test~* Symptoms of depression using 2 items from the PHQ 9~* Symptoms of anxiety using two items from the GAD~* Short form self-compassion scale
Study NCT05388565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Domestic Violence Enhanced Perinatal Care Program
Description: Our intervention consists of four major components: a) information about IPV and its effects on maternal and infant health, b) danger assessment, c) options and safety plan, and d) resources.
Study NCT05388565 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Usual perinatal care (e.g., prenatal health education) and a list of resource information (e.g., crisis lines, local IPV and mental health resources)
Study NCT06234735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity in the community
Description: Supervised and guided PA sessions in the community setting using public resources such as parks, sports facilities, etc.
Study NCT06234735 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: Conventional protocol for lung cancer and PA recommendations.
Study NCT04683198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
Study NCT04683198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
Study NCT04683198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
Study NCT04683198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
Study NCT05787353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.
Study NCT04730986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED GOAL Nursing
Description: A brief (\<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
Study NCT06367868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: After 5 ml CSF Drainage
Description: Optic Nerve Sheath Diameter and Intracranial Pressure measurements will be after 5 ml CSF drainage
Study NCT05811494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lexo
Description: Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
Study NCT05811494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
Study NCT05811494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Mill
Description: C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
Study NCT05811494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body-weight support treadmill
Description: Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
Study NCT04987853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical and functional analysis
Description: General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~* EchoCG + strain~* CT scan of the lungs~* Holter~* SMAD~* Kidney ultrasound~* Ultrasound~* Doppler ultrasonography of veins and arteries~* Chalder Scale, EQ Questionnaire
Study NCT04987853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological analysis
Description: Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4. Laboratory research methods:~1. The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~2. Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes).
Study NCT04987853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunological analysis:
Description: A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
Study NCT04987853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis:
Description: Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
Study NCT03797040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: PLX-R18: Allogeneic ex vivo expanded placental stromal cells
Study NCT04901403 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Parents will be provided with information about Earned Income Tax Credits and budgeting
Study NCT04901403 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home visiting
Description: Parents as Teachers home visiting program
Study NCT05535127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Palpation with  laryngeal handshake technique
Description: Information alredy included
Study NCT05535127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Palpation strategy plus sequential ultrasound
Description: Information alredy included
Study NCT05535127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Identification of the cricothyroid membrane with routine ultrasound
Description: Information alredy included
Study NCT05961436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG block
Description: Using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.
Study NCT05961436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FN block
Description: Using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
Study NCT05267054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: administered intravenously
Study NCT05267054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered intravenously
Study NCT05267054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: administered intravenously
Study NCT04659408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multistrain probiotic preparation
Description: One sachet daily, containing 3 grams of the freeze-dried multispecies probiotic Bactosan for a period of four weeks. One sachet will be mixed with 50-100 ml water and taken daily before breakfast or dinner. Bactosan contains the following eight bacterial strains: Bifidobacterium lactis W51, Bifidobacterium lactis W52, Enterococcus faecium W54, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Lactobacillus plantarum W21, Lactobacillus salivarius W24 and Lactococcus lactis W19, with a total viable cell count of 1 × 109 cfu/gram, and therefore 3 × 109 cfu/daily dose.
Study NCT04659408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Bran
Description: 5 grams (one teaspoon) daily of the oat bran together with a meal of preference. The oat bran can be added to the usual breakfast cereal, yoghurt, pancakes, juice, milk, salad sauce or in an omelette.
Study NCT05763719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabbits for Resilience (RFR) + HIKA
Description: Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household
Study NCT05763719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabbits for Resilience (RFR) only
Description: Economic empowerment program using animal husbandry with young adolescents
Study NCT05763719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIKA Healthy Relationship Program
Description: Healthy relationship program for parents/couples
Study NCT06013475 — intervention group
Intervention type: DRUG
Intervention: Apalutamide
Description: Decision by the treating physician
Study NCT06013475 — intervention group
Intervention type: DRUG
Intervention: Darolutamide (BAY 1841788)
Description: Decision by the treating physician
Study NCT06013475 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide
Description: Decision by treating physician
Study NCT05281562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.
Study NCT05281562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine Powder
Description: Daily dose of 4.5 grams L-Arginine, powder form.
Study NCT05281562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Daily dose of 500 mg Vitamin C, powder form.
Study NCT05024760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
Study NCT05024760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
Study NCT06409949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Walking assessment
Description: Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)
Study NCT06060392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pill
Description: Patient will receive oral semaglutide
Study NCT05844137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAFLD Education
Description: NAFLD Education
Study NCT05844137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet/lifestyle support
Description: diet/lifestyle support
Study NCT05844137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2D medication management
Description: T2D medication management
Study NCT05844137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: clinically-indicated liver testing and care
Description: clinically-indicated liver testing and care
Study NCT05158465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Intervention will include 3 one-on-one motivational interviewing sessions and 3 follow-up calls with a trained MI health educator. These sessions aim to promote better oral hygiene and oral health.
Study NCT06223542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06223542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT06223542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06223542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06223542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06071195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate Cancer Patients
Description: see arm/group description
Study NCT06409949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Walking assessment
Description: Participating patients will undergo the following evaluations at baseline and after six months of treatment with MitoQ or placebo:~Assessment of walking impairment: Evaluation of treadmill maximum walking distances, six-minute walking distance, and daily physical activity (average steps taken daily)
Study NCT06409949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QOL Survey
Description: Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36
Study NCT06409949 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QOL Survey
Description: Assessment of quality of life: Survey of Quality of life with the Walking Impairment Questionnaire and Short Form 36
Study NCT04775407 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling
Description: IgM og IgG analysis
Study NCT06223542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UAE Inhibitor TAK-243
Description: Given IV
Study NCT06645197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNUG01
Description: Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
Study NCT06409949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ankle pressure at rest and after stress
Description: Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index
Study NCT06409949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Ankle pressure at rest and after stress
Description: Assessment of leg hemodynamics: Evaluation of post-occlusive ankle pressure and ankle/brachial index
Study NCT06303310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze Stability Exercises
Description: Group A ( Gaze Stability Exercise+ Routine Physical Therapy) Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.(16)
Study NCT06303310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optokinetic Exercises
Description: Group B (Optokinetic Exercises+Routine Physical Therapy) Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks
Study NCT06303310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Routine Physical Therapy
Study NCT05783375 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ADUNU program for delivery of RHD care services
Description: The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.
Study NCT04571320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer STRIPES
Description: See arm description.
Study NCT06409949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Oxygen
Description: Evaluation of calf muscle heme oxygen saturation
Study NCT06409949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Oxygen
Description: Evaluation of calf muscle heme oxygen saturation
Study NCT06409949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum MitoQ Level
Description: Evaluation of serum concentrations of MitoQ
Study NCT06409949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Serum MitoQ Level
Description: Evaluation of serum concentrations of MitoQ
Study NCT06409949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle Biopsy
Description: Needle biopsy of the calf muscle
Study NCT06409949 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Needle Biopsy
Description: Needle biopsy of the calf muscle
Study NCT04571320 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced School Services as Usual
Description: see arm description.
Study NCT05172102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise, Aerobic exercises
Description: 6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
Study NCT04277689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain signal data collection
Description: Collection of speech related electrophysiological data at the time of DBS.
Study NCT04716907 — intervention group
Intervention type: GENETIC
Intervention: Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region
Description: DNA extraction from blood samples, PCR and Sequencing
Study NCT04716907 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
Study NCT05779007 — intervention group
Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone
Study NCT05779007 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib
Study NCT04716907 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT Scan
Description: Thymus and lung imaging
Study NCT04716907 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bronchial fibroscopy
Description: Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
Study NCT06129175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neuroncell-EX
Description: Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
Study NCT06129175 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
Study NCT05397431 — intervention group
Intervention type: DRUG
Intervention: Lanadelumab
Description: Lanadelumab 300 mg, subcutaneous injection every 2 weeks
Study NCT05116878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
Study NCT05116878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
Study NCT06557772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlitelimab
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Study NCT04502433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUROSURF® (poractant alfa)
Description: Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW.
Study NCT06557772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: SC injection
Study NCT06557772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SIGE
Description: Pharmaceutical form: Capsule Route of administration: Oral